Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIb-IV melanoma.
Merrick I. Ross
Consultant or Advisory Role - Amgen
Honoraria - Paradigm Medical Communications
Research Funding - Amgen
Robert Hans Ingemar Andtbacka
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Igor Puzanov
Consultant or Advisory Role - Amgen
Mohammed M. Milhem
No relevant relationships to disclose
Frances A. Collichio
Consultant or Advisory Role - Amgen
Research Funding - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Morphotek; Novartis
Keith A. Delman
Research Funding - Amgen
R Dirk Noyes
No relevant relationships to disclose
Jonathan S. Zager
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Expert Testimony - Gill & Chamas, LLC
Lee D. Cranmer
Consultant or Advisory Role - BioVex
Lynn E. Spitler
Consultant or Advisory Role - BioVex
Eddy C. Hsueh
No relevant relationships to disclose
David W. Ollila
No relevant relationships to disclose
Thomas Amatruda
No relevant relationships to disclose
Lisa Chen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jennifer L. Gansert
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Howard L Kaufman
Consultant or Advisory Role - Amgen